Treatment and survival of elderly patients with stage I-II pancreatic cancer: a report of the EURECCA pancreas consortium

Groen, J.V.
Douwes, T.A.
Eycken, E. van
Geest, L.G.M. van der
Johannesen, T.B.
Besselink, M.G.
Koerkamp, B.G.
Wilmink, J.W.
Bonsing, B.A.
Portielje, J.E.A.
Velde, C.J.H. van de
Bastiaannet, E.
Mieog, J.S.D.

Open link

Publication date

May 2020

DOI

10.1245/s10434-020-08539-x

Publisher

Springer Science and Business Media LLC

Abstract

Background Elderly patients with pancreatic cancer are underrepresented in clinical trials, resulting in a lack of evidence. Objective The aim of this study was to compare treatment and overall survival (OS) of patients aged >= 70 years with stage I-II pancreatic cancer in the EURECCA Pancreas Consortium. Methods This was an observational cohort study of the Belgian (BE), Dutch (NL), and Norwegian (NOR) cancer registries. The primary outcome was OS, while secondary outcomes were resection, 90-day mortality after resection, and (neo)adjuvant and palliative chemotherapy. Results In total, 3624 patients were included. Resection (BE: 50.2%; NL: 36.2%; NOR: 41.3%; p = 70 years with stage I-II pancreatic cancer, between the population-based cance...